Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas

Translocation renal cell carcinoma (tRCC) is a rare subtype of kidney tumour characterized by translocations involving the transcription factor TFE3 or TFEB. tRCC was introduced into the World Health Organization classification in 2004, but much is still unknown about the natural history, clinicopathological features and outcomes of the disease. The aim of this study was to describe the landscape of fusion transcript in a large single‐institution series of fluorescence in‐situ hybridization (FISH)‐confirmed tRCCs and then to compare it to morphological and clinical data.

[1]  C. Antonescu,et al.  RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-negative TFE3 FISH , 2017, The American journal of surgical pathology.

[2]  Xiao-jun Zhou,et al.  Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3 , 2017, The American journal of surgical pathology.

[3]  C. Antonescu,et al.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers , 2016, The American journal of surgical pathology.

[4]  M. Sibony,et al.  Identification by FFPE RNA‐Seq of a new recurrent inversion leading to RBM10‐TFE3 fusion in renal cell carcinoma with subtle TFE3 break‐apart FISH pattern , 2016, Genes, chromosomes & cancer.

[5]  Steven J. M. Jones,et al.  Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.

[6]  R. Mehra,et al.  MiT Family Translocation-Associated Renal Cell Carcinoma: A Contemporary Update With Emphasis on Morphologic, Immunophenotypic, and Molecular Mimics. , 2015, Archives of pathology & laboratory medicine.

[7]  N. Dimitrova,et al.  Identification of a novel PARP14‐TFE3 gene fusion from 10‐year‐old FFPE tissue by RNA‐seq , 2015, Genes, chromosomes & cancer.

[8]  R. Jia,et al.  Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review. , 2015, Future oncology.

[9]  Hongqian Guo,et al.  Xp11.2 translocation renal cell carcinomas in young adults , 2015, BMC Urology.

[10]  P. Argani.  MiT family translocation renal cell carcinoma. , 2015, Seminars in diagnostic pathology.

[11]  Choung-Soo Kim,et al.  Clinicopathological features of Xp11.2 translocation renal cell carcinoma , 2015, Korean journal of urology.

[12]  X. Leroy,et al.  Cutaneous metastases during an aggressive course of Xp11.2 translocation renal cell carcinoma in a teenager , 2014, Pediatric blood & cancer.

[13]  Soroush Rais-Bahrami,et al.  Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers , 2014, Nature Reviews Urology.

[14]  Christian Ruiz,et al.  MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration‐resistant prostate cancer , 2014, International journal of cancer.

[15]  Erika J. Thompson,et al.  Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes , 2014, Clinical Cancer Research.

[16]  M. Ladanyi,et al.  Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage , 2014, Modern Pathology.

[17]  Hiroyuki Aburatani,et al.  Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome , 2014, International journal of cancer.

[18]  P. Argani,et al.  t(6;11) Renal Cell Carcinoma (RCC): Expanded Immunohistochemical Profile Emphasizing Novel RCC Markers and Report of 10 New Genetically Confirmed Cases , 2014, The American journal of surgical pathology.

[19]  Hong-cheng Song,et al.  Biological characteristics of pediatric renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions. , 2014, Journal of pediatric surgery.

[20]  P. Sathe,et al.  Xp11 translocation renal cell carcinoma. , 2013, Indian journal of pathology & microbiology.

[21]  M. Ladanyi,et al.  Utilization of a TFE3 Break-apart FISH Assay in a Renal Tumor Consultation Service , 2013, The American journal of surgical pathology.

[22]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[23]  The Cancer Genome Atlas Research Network.  COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[24]  M. Chevallier,et al.  Diagnosis of Xp11 translocation renal cell carcinomas in adult patients under 50 years: interest and pitfalls of automated immunohistochemical detection of TFE3 protein. , 2013, Pathology, research and practice.

[25]  J. Cheville,et al.  ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients , 2012, Modern Pathology.

[26]  M. Ladanyi,et al.  Molecular Confirmation of t(6;11)(p21;q12) Renal Cell Carcinoma in Archival Paraffin-embedded Material Using a Break-apart TFEB FISH Assay Expands its Clinicopathologic Spectrum , 2012, The American journal of surgical pathology.

[27]  W. Linehan,et al.  Translocation Renal Cell Carcinomas in Adults: A Single-institution Experience , 2012, The American journal of surgical pathology.

[28]  J. Cheville,et al.  TFE3 Rearrangements in Adult Renal Cell Carcinoma: Clinical and Pathologic Features With Outcome in a Large Series of Consecutively Treated Patients , 2012, The American journal of surgical pathology.

[29]  T. Klatte,et al.  Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. , 2012, American journal of clinical pathology.

[30]  P. Schirmacher,et al.  Molecular heterogeneity of TFE3 activation in renal cell carcinomas , 2012, Modern Pathology.

[31]  M. Ladanyi,et al.  Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions , 2011, Modern Pathology.

[32]  A. Zlotta,et al.  Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome , 2011, BJU international.

[33]  Gudrun Schleiermacher,et al.  Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors. , 2011, The Journal of urology.

[34]  M. Ladanyi,et al.  A Distinctive Subset of PEComas Harbors TFE3 Gene Fusions , 2010, The American journal of surgical pathology.

[35]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma (RCC): Extended Immunohistochemical Profile Emphasizing Novel RCC Markers , 2010, The American journal of surgical pathology.

[36]  M. Ladanyi,et al.  Melanotic Xp11 Translocation Renal Cancers: A Distinctive Neoplasm With Overlapping Features of PEComa, Carcinoma, and Melanoma , 2009, The American journal of surgical pathology.

[37]  Y. Ishikawa,et al.  Adult Xp11 Translocation Renal Cell Carcinoma Diagnosed by Cytogenetics and Immunohistochemistry , 2009, Clinical Cancer Research.

[38]  Karl J. Dykema,et al.  Renal Translocation Carcinomas: Clinicopathologic, Immunohistochemical, and Gene Expression Profiling Analysis of 31 Cases With a Review of the Literature , 2008, The American journal of surgical pathology.

[39]  M. Ladanyi,et al.  Xp11 Translocation Renal Cell Carcinoma in Adults: Expanded Clinical, Pathologic, and Genetic Spectrum , 2007, The American journal of surgical pathology.

[40]  M. Ladanyi,et al.  The evolving story of renal translocation carcinomas. , 2006, American journal of clinical pathology.

[41]  Antonio Lopez-Beltran,et al.  2004 WHO classification of the renal tumors of the adults. , 2006, European urology.

[42]  M. Ladanyi,et al.  Translocation carcinomas of the kidney. , 2005, Clinics in laboratory medicine.

[43]  M. Ladanyi,et al.  Renal Carcinomas With the t(6;11)(p21;q12): Clinicopathologic Features and Demonstration of the Specific Alpha-TFEB Gene Fusion by Immunohistochemistry, RT-PCR, and DNA PCR , 2005, The American journal of surgical pathology.

[44]  M. Ladanyi,et al.  Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms With TFE3 Gene Fusions: A Sensitive and Specific Immunohistochemical Assay , 2003, The American journal of surgical pathology.

[45]  M. Ladanyi,et al.  PRCC-TFE3 Renal Carcinomas: Morphologic, Immunohistochemical, Ultrastructural, and Molecular Analysis of an Entity Associated With the t(X;1)(p11.2;q21) , 2002, The American journal of surgical pathology.

[46]  M. Ladanyi,et al.  Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. , 2001, The American journal of pathology.